...September to acquire CRO MediSync BioServices Inc. in a stock deal valued at $7.5 million. Vyteris...
...acquisition in April. Lidosite is a lidocaine HCl and epinephrine iontophoretic patch. At March 31, Vyteris...
...in cash and a three-month operating loss of $1.3 million (see BioCentury, Sept. 27, 2010). Vyteris Inc....

...Drug delivery company Vyteris plans to acquire CRO MediSync in a stock deal valued at $7.5...
...deal was announced. MediSync stock and debt holders will receive 25 million new Vyteris shares. Vyteris...
...from MediSync will be appointed to Vyteris' board. MediSync BioServices Inc. , Delray Bay, Florida Vyteris Inc....

...The institute's tech transfer arm, Georgia Tech Research Corp., granted Vyteris an option for an exclusive...
...fabrication technology Vyteris could manufacture microstructures under mild conditions that do not harm encapsulated drugs. Vyteris...
...technologies. The university is eligible for milestones and royalties. Further financial terms were not disclosed. Vyteris Inc....

...The partners will apply Vyteris' transdermal delivery technology to Zealand's peptide optimization technology to test the...
...the companies could decide to further develop and commercialize peptides incorporating the drug delivery technology. Vyteris Inc....

...As part of a restructuring announced in February, Vyteris is seeking to secure another peptide development...
...Patch coupled with an undisclosed peptide completed Phase I trials in female infertility this year. Vyteris...
...partner Ferring Pharmaceuticals A/S (Copenhagen, Denmark) to start Phase II trials of the transdermal patch. Vyteris...

...Novo Nordisk (CSE:NVO; NYSE:NVO) to develop next-generation versions of Factors VIIa, VIII and IX 2/1/08 Vyteris...